HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial.

AbstractBACKGROUND AND AIMS:
An inverse relationship between (serum) total bilirubin and risk of cardiovascular disease has been reported previously, but longitudinal data on overweight and obese patients are lacking. We have investigated the relationship between total bilirubin and cardiovascular adverse events in a large group of patients with risk factors for cardiovascular disease who were enrolled in a large weight loss trial.
METHODS AND RESULTS:
Data from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, including almost 10.000 overweight/obese high cardiovascular risk patients, were used. The relationship between total bilirubin level at screening and the primary outcome (i.e. non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death) for the entire study period was investigated using Cox proportional hazards models. The population was divided into four groups based on total bilirubin levels (normal range 5-25 μmol/L). Time-dependent Cox analyses were also performed to adjust for weight loss over time. Initial analyses adjusted for sex, age and treatment allocation showed significantly reduced hazard ratios of 0.80 (95% confidence interval 0.68-0.94), 0.73 (0.62-0.86) and 0.77 (0.65-0.91), for the three higher total bilirubin groups: >8 and ≤10 μmol/L, >10 and ≤13 μmol/L and >13 μmol/L (5-95 interpercentile range for total bilirubin at screening; 6-19 μmol/L), compared to the lowest total bilirubin group ≤8 μmol/L. When adjusting for classical cardiovascular risk factors, estimates increased towards unity. Additional adjustment for indicators of liver function did not alter the results. A time-dependent Cox model, adjusted for weight loss, demonstrated a similar trend.
CONCLUSION:
Bilirubin was not a risk-factor independent from other traditional cardiovascular risk-factors in our population.
AuthorsM E Jørgensen, C Torp-Pedersen, N Finer, I Caterson, W P T James, U F Legler, C Andersson
JournalNutrition, metabolism, and cardiovascular diseases : NMCD (Nutr Metab Cardiovasc Dis) Vol. 24 Issue 6 Pg. 656-62 (Jun 2014) ISSN: 1590-3729 [Electronic] Netherlands
PMID24534073 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Bilirubin
Topics
  • Aged
  • Bilirubin (blood)
  • Body Mass Index
  • Cardiovascular Diseases (epidemiology, etiology, mortality, prevention & control)
  • Cohort Studies
  • Double-Blind Method
  • Female
  • Heart Arrest (epidemiology, etiology, prevention & control, therapy)
  • Humans
  • Incidence
  • Life Style
  • Male
  • Middle Aged
  • Mortality
  • Myocardial Infarction (epidemiology, etiology, mortality, prevention & control)
  • Obesity (blood, physiopathology, therapy)
  • Overweight (blood, physiopathology, therapy)
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Factors
  • Stroke (epidemiology, etiology, mortality, prevention & control)
  • Up-Regulation
  • Weight Loss

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: